Drug Details
| General Information of the Drug (ID: DR1391) | ||||
|---|---|---|---|---|
| Name |
N, N-dimethyl-D-erythro-sphingosine
|
|||
| Disease | Colon cancer [ICD-11: 2B90] | Investigative | [1] | |
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Ceramide | Ananas comosus | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Increase | Mitochondrial membrane potential loss | ||||
| In-vitro Model | LL/2 (LLC1) | CVCL_4358 | Malignant tumors | Mus musculus | ||
| Experimental
Result(s) |
The radiosensitizing activity of ceramide/DMS on LLC cells most likely reflects the dominance of pro-apoptotic signals related to the mitochondria-dependent pathway. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Bacterial Pseudomonas Elastase (Bact lasB) | Molecule Info | [3] | |
